Gene Biotherapeutics, Inc.
CRXM · OTC
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Market Cap | $916 | $2,680 | $739 | $1,429 |
| - Cash | $386 | $0 | $82 | $49 |
| + Debt | $1,260 | $1,121 | $1,066 | $1,231 |
| Enterprise Value | $1,791 | $3,801 | $1,723 | $2,611 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$2 | -$58 | -$63 | -$66 |
| % Margin | – | – | – | – |
| EBITDA | -$1,260 | -$779 | -$450 | -$2,010 |
| % Margin | – | – | – | – |
| Net Income | -$518 | $867 | -$435 | -$1,894 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.024 | 0.06 | -0.03 | -0.13 |
| % Growth | -140% | 298% | 76.8% | – |
| Operating Cash Flow | -$1,133 | -$137 | -$452 | -$1,062 |
| Capital Expenditures | -$3 | $0 | $0 | $0 |
| Free Cash Flow | -$1,136 | -$137 | -$452 | -$1,062 |